Liposomal bupivacaine or Exparel (Pacira Biosciences) is a long-lasting nonopioid analgesic that was initially utilized as an infiltrative agent but has more recently become U.S. Food and Drug Administration (FDA) approved for use in interscalene brachial plexus nerve blockade as well as infiltrative blockade. Delivery in this form is reported to provide up to 72 hours of extended-release bupivacaine. Exparel's use as a regional anesthetic has also become increasingly common and has shown promise when utilized in Anterior Cruciate Ligament (ACL) reconstruction.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
154
30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States
Postoperative Pain
Daily postoperative VAS (visual analog scale for pain) scale will be collected from participants to assess pain
Time frame: 14 days
Postoperative opioid use
assessed using a participant daily diary of how much medication was taken daily for pain
Time frame: 14 days
Postoperative Pain #2
Daily postoperative NRS (numerical rating scale for pain) scale will be collected from participants to assess pain
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block